ArticleMolecular biology reports2025
Voltage-Gated sodium channel Nav1.6 mediates glioblastoma proliferation and migration via Na
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ion Channel-Targeting Modulators in Glioma: Pharmacological Advances and Therapeutic Perspectives.International journal of molecular sciences · 2026Review
- From Marine Peptides to Oncology: The Therapeutic Potential of Conotoxins in Cancer Treatment.Chemistry & biodiversity · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma (GBM) is an aggressive brain cancer with limited treatment options and a poor prognosis. Voltage-gated sodium channels, particularly Nav1.6 (SCN8A), have been implicated in tumor progression across various cancers. This study investigates the role of Nav1.6 in promoting GBM proliferation and migration via Na⁺/H⁺ exchanger-1 (NHE1), and its regulation of ERK and AKT signaling pathways to identify potential therapeutic strategies. METHODS AND
resultsImmunohistochemistry revealed high Nav1.6 expression in glioma tissues, peaking in grade IV GBM. Human GBM cell lines (U251, U138, U87) were used to explore the functional roles of Nav1.6 and NHE1 through siRNA-mediated silencing and pharmacological modulation. Quantitative PCR and Western blot confirmed the effective silencing of both targets and the downstream effects on protein expression. CCK8 and EdU DNA cell proliferation assays showed that inhibition of Nav1.6 or NHE1 significantly suppressed cell proliferation. Wound healing and Transwell migration assays demonstrated reduced cell motility upon gene silencing or treatment with TTX and EIPA. Flow cytometry and Caspase-3 analysis confirmed enhanced apoptosis following dual inhibition. Conversely, activation of Nav1.6 by ATXII promoted proliferation and migration, effects reversed by NHE1 downregulation. Importantly, combined suppression of Nav1.6 and NHE1 led to significant downregulation of phosphorylated AKT and ERK1/2, suggesting their cooperative role in modulating survival signaling in GBM.
conclusionNav1.6 promotes GBM progression by regulating ion homeostasis via NHE1 and activating AKT/ERK pathways. Dual targeting of Nav1.6 and NHE1 may offer a promising strategy to inhibit proliferation and induce apoptosis in GBM.
Indexed as
Identifiers
41045405What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.